Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin

• Published in: The Journal of pediatrics 2021-12, Vol.239, p.161-167.e5
• Main Authors: Gawrieh, Samer, Harlow, Kathryn E., Pike, Francis, Yates, Katherine P., Wilson, Laura A., Cummings, Oscar W., Rosenberg, William M., Chalasani, Naga, Molleston, Jean P.
• Format: Article
• Language: English
• Subjects: Adolescent; Area Under Curve; Biopsy; Child; Double-Blind Method; Drug Therapy, Combination; ELF; Female; Follow-Up Studies; Humans; Hypoglycemic Agents - therapeutic use; Liver - pathology; Liver Cirrhosis - diagnosis; Liver Cirrhosis - pathology; Logistic Models; Male; metformin; Metformin - therapeutic use; NASH; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - pathology; Odds Ratio; PIIINP; ROC Curve; Severity of Illness Index; Treatment Outcome; vitamin E; Vitamin E - therapeutic use; Vitamins - therapeutic use
• ISSN: 0022-3476; 1097-6833
• DOI: 10.1016/j.jpeds.2021.08.012

To study the diagnostic performance of the enhanced liver fibrosis score (ELF) for detecting different stages of fibrosis and its usefulness in detecting histologic response to vitamin E or metformin in children with nonalcoholic fatty liver disease who participated in the Vitamin E or Metformin for the Treatment Of NAFLD In Children (TONIC) trial. ELF was measured at baseline and weeks 24, 48, and 96 on sera from 166 TONIC participants. Associations between ELF with baseline and end of trial (EOT) fibrosis stages and other histologic features were assessed using χ2 tests and logistic regression models. ELF was significantly associated with severity of fibrosis at baseline and EOT. ELF areas under the curve for discriminating patients with clinically significant and advanced fibrosis were 0.70 (95% CI, 0.60-0.80) and 0.79 (95% CI, 0.69-0.89), respectively. A 1-unit decrease in ELF at EOT was associated with overall histologic improvement (OR, 1.86; 95% CI, 1.11-3.14; P = .02), resolution of steatohepatitis (OR, 1.88; 95% CI, 1.09-3.25; P = .02), improvement in steatosis grade (OR, 1.76; 95% CI, 1.06-2.82; P = .03), and hepatocellular ballooning (OR, 1.79; 95% CI, 1.06-3.00; P = .03), but not with improvement in fibrosis stage (OR, 1.26; 95% CI, 0.78-2.03; P = .34). ELF was associated with fibrosis stage in children who participated in TONIC. Although not associated with improvement in fibrosis, a decrease in ELF at EOT was associated with Nonalcoholic Steatohepatitis resolution and improvement in nonalcoholic fatty liver disease histology. ELF may be a useful noninvasive test to monitor treatment response in children with nonalcoholic fatty liver disease.